Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.

Key facts

Study ID

NCT01096940

Run by

AstraZeneca

People needed

44

Starts

2010-03-01

Expected to finish

2010-08-01

Last updated by the study team

2010-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a clinical diagnosis of T2DM for at least 1 year, treated with any metformin or metformin with one other oral anti-diabetic drug (OAD)
• Body mass index between greater than or equal to 19 and less than or equal to 42 kg/m2
• HbA1c greater than 6.5% at enrollment

You may not qualify if…

• Clinically significant illness or clinically relevant trauma, as judged by the Investigator, within 2 weeks before the first administration of the IP
• Significant cardiovascular event within the last 6 months prior to enrollment (eg, myocardial infarction/acute coronary syndrome, revascularisation procedure, stroke or transient ischaemic attack) or heart failure New York Heart Association (NYHA) class III-IV

Where it is running

• Research Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.